Hernández-Da Mota SE, Chacón-Lara A, Hernández-Vázquez E

Language: Spanish
References: 26
Page: 152-157
PDF size: 100.93 Kb.

ABSTRACT

Purpose: To evaluate the safety and efficacy of combined phacoemulsification and triamcinolone assisted vitrectomy with application of bevacizumab in patients with cataract and diffuse diabetic macular edema.
Methods: In this prospective, non-randomized, interventional case series we included 13 eyes of 13 patients with subcapsular cataract and diffuse macular edema and they underwent phacoemulsification, 25G triamcinolone assisted vitrectomy, endophotocoagulation and bevacizumab injection at the end of the procedure. We performed a follow-up with basal best corrected visual acuity, fluorescein angiography, optical coherent tomography at two weeks, one, three and six months of having performed the procedure.
Results: An improvement in best-corrected visual acuity of at least two lines was seen in 11 patients. The basal average central macular thickness was 358.23 µ (SD 50 µ) while at the end of follow-up it was of 216.6 µ (SD 23.2 µ).
Conclusion: This combined surgical and pharmacological treatment in the six-month period of follow-up resulted in an improvement of central macular thickness and non-progression of diabetic retinopathy. Larger, comparative series are mandatory to establish the real efficacy of this treatment approach.

REFERENCES

1. Diabetes control and complications trial Research Group. The effect of intensive treatment of diabetes on the development and progression of the long term complications in insulin dependent diabetes mellitus. N Eng J Med 1993; 329:977-986.

2. Diabetes control and complications trial Research Group.The relationship on glicemic exposures to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44:968-993.

3. Diabetes control and complications trial Research Group. Perspectives in Diabetes: the absence of a glycemic threshold for the development of long term complications: the perspective of the diabetes Control and Complications Trial.

4. DRS report no. 8 The Diabetic Retinopathy Study Research Group. Ophthalmology 1981; 88:583-600.

5. Early treatment of Diabetic Retinopathy Study. Report no. 9 Early treatment of Diabetic Retinopathy Study Group. Opthalmology 1991; 98:766-785.

6. Early treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema ETDRS report no. 1. Arch Ophthalmol 1985; 103:1796-1806.

7. Early treatment Diabetic Retinopathy Study Research Group. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy. ETDRS report no. 3. Int Ophthalmol Clin 1987; 27:254-264.

8. Early treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema ETDRS report no. 4. Int Ophthalmol Clin 1987; 27:265-272.

9. Early treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. ETDRS report no. 2. Ophthalmology 1987; 94:761-774.

10. Han DP, Miller WF, Burton TC. Submacular fibrosis after photocoagulation for diabetic macular edema. Am J Ophthalmol 1992; 113:513-521.

11. Ai E. Current management of diabetic retinopathy. West J Med 1992; 157(1):67-70.

12. La Heij EC, Hendrikse F, Kessels AG, Derhaag PJ. Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. Graefes Arch Clin Exp Ophthalmol 2001; 239(4):264-70.

13. Thomas D, Bunce C, Moorman C, Laidlaw DA. A randomized controlled feasibility trial of vitrectomy versus laser for diabetic macular edema. Br J Ophthalmol 2005; 89(1):81-6.

14. Patel JL, Hykin PG, Schadt M y cols. Diabetic macular edema: pilot randomized trial of pars plana vitrectomy versus macular argon photocoagulation. Eye 2005; 29.

15. Martidis A, Duker JS, Greenberg PB y cols. Intravitreal injection of triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109:920-927.

16. Jonas JB, Kreissing I, Sofker A y cols. Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 2003; 121: 57-61.

17. Massin P, Audrin F, Haouchine B y cols. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema. Ophthalmology 2004; 111: 218-225.

18. Shah GK, Rosenblatt BG, Blinder KG y cols. Triamcinolone assisted internal limiting membrane peeling. Retina; 25(8): 972-5.

19. Doi N, Uemura A, Nakao K, Sakamoto T. Vitreomacular adhesion and the defect in posterior cortex visualized by triamcinolone-assisted vitrectomy. Retina 2005; 25(6):742-5.

20. Mathews MK, Merges C, McLeod DS y cols. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci 1997; 38:2729-2741.

21. Ferrara N, Hillan KG, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody. Biochem Biophys Res Commun 2005; 333(2):289-91.

22. Gupta A, Gupta V. Diabetic maculopathy and cataract surgery. Ophthalmol Clin North Am 2001; 14(4):625-37.

23. Squirrell D, Bhola R, Bush J, Winder S, Talbot JF. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. Br J Ophthalmol 2002; 86(5):565-71.

24. Kreper K, Biowski R, Scherey S y cols. Cataract surgery in patients with diabetic retinopathy: visual outcome, progression of diabetic retinopathy, and incidence of diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2002; 240(9):735-740.

25. Patel JI, Hykin PG, Cree IA. Diabetic cataract removal: postoperative progression of maculopathy—growth factor and clinical analysis. Br J Ophthalmol 2006; 90(6):697-701.

26. Itakura I, Kishi S, Kotajima N, Murakami N. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferativa diabetic retinopathy after vitrectomy. Ophthalmology 2004; 111:1880-84.